Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. entered into an Amended and Restated Management Services Agreement (A&R MSA) with Ljungaskog Consulting AB, owned by CEO Thomas H. Jensen, effective June 1, 2026. The A&R MSA updates compensation, bonus, and termination provisions for the CEO's services. Key changes include a revised annual base salary, elimination of a signing bonus, and increased termination payments for the consultant.

Allarity Therapeutics reported a net loss of $(2.75) million for the first quarter of 2026, a slight increase from $(2.73) million in the prior year, with a basic and diluted loss per share of $(0.17). The company significantly increased its cash position by securing $20.0 million through new promissory notes, bringing total cash and restricted cash to $29.8 million. This capital infusion is expected to fund operations for at least the next twelve months, despite ongoing negative cash flows from operations.

Allarity Therapeutics announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib is progressing on schedule, with completion expected no later than the third quarter of 2026. This milestone is crucial for supporting the planned pivotal trial in advanced ovarian cancer and accelerating stenoparib toward FDA approval, especially given its Fast Track designation. The company also confirmed that all manufacturing-related payments have been completed, with no additional cash outlays anticipated.

Allarity Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026. Stockholders of record as of May 7, 2026, are eligible to vote on several key proposals. These include the election of a Class I director, ratification of the independent auditor, an amendment to increase shares under the 2021 Equity Incentive Plan, and an advisory vote on executive compensation. Additionally, the company seeks approval for a common stock issuance exceeding Nasdaq limits and an amendment to limit officer liability.

Allarity Therapeutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to stenoparib. This patent is expected to be formally granted within three months and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP® test. This is a significant step in the company's global strategy to expand and protect the commercial potential of stenoparib, especially as it seeks to accelerate approval for Ovarian and other cancers.

Allarity Therapeutics announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's DRP companion diagnostic specific to stenoparib. This patent is expected to be formally granted within three months and would provide exclusivity at least into 2039 for stenoparib when used with the DRP companion diagnostic. This represents a significant step in Allarity's global strategy to expand and protect the commercial potential of stenoparib, particularly in the crucial U.S. market, as the company accelerates its development for Ovarian and other cancers.

Allarity Therapeutics announced the publication of two scientific posters presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations highlight stenoparib's potential in colorectal cancer through WNT pathway modulation and new predictive data linking the Stenoparib-DRP® companion diagnostic to enhanced overall survival in ovarian cancer patients. These findings underscore the company's ongoing research and development efforts for its lead drug candidate.

Allarity Therapeutics announced new data for its drug stenoparib, presented at the AACR Annual Meeting 2026. The data highlight stenoparib's potential in colorectal cancer by modulating the WNT pathway and show its proprietary Drug Response Predictor (DRP®) is associated with enhanced overall survival in ovarian cancer patients. These findings reinforce the value of DRP-based patient selection and stenoparib's unique mechanism of action, addressing significant unmet medical needs in oncology.